Nunaps raises USD 4.2M; Arcutis files for USD 100M IPO

A South Korean startup therapeutics company Nunaps has successfully raised USD 4.2 Million around 5 billion won in a Series A round. 

The investment was made by the K Partners, KTB Network, and K2 Investment Partners. Nunaps is digital therapeutics and is planning to use the funds to build its digital therapeutics platform to diagnose neurological disorders. 

Nunap Vision is a SaMD (Software as a Medical Device) which utilises HMD VR. Its clinical efficacy has already been demonstrated, however, the pivotal multi-centre, double-blind, randomised, and a placebo-controlled clinical trial will further validate the product. The product is designed to provide perception training for the detection of damages in the brain, such as strokes through virtual reality. 

The company is planning to advance the R&D and pipeline of various brain disorders and develop customised therapy approaches.

Arcutis Biotherapeutics, a Phase III Biotech company has filed for USD 100 Million IPO to develop therapies for Skin diseases.

The company is focusing on advancing the Derma market by developing and commercialising the therapies to treat skin diseases. 

Arcutis’s lead therapy product ARQ-151, which is in Phase III clinical trials is indicated for plaque psoriasis. The company is also a developing topical therapy roflumilast which is a selective phosphodiesterase type 4, or PDE4, inhibitor, and again is a treatment for plaque psoriasis, including psoriasis in areas such as the groin, axillae and the inframammary regions, as well as atopic dermatitis. 

Currently, derma market has high unmet medical needs such as the absence of standard approved therapies, and proper diagnosis of different diseases.

Merck and Pfizer have announced the results of Phase III clinical studies of BAVENCIO for the treatment of untreated locally advanced or metastatic urothelial carcinoma (UC). 

Bavencio (avelumab) a therapy under simulations run by Merck KGaA, and Pfizer have announced positive results of the Phase III JAVELIN Bladder 100 study. The study has met its primary end point of overall survival (OS). 

Bavencio has received first-line maintenance therapy and best supportive care for the patients with previously untreated locally advanced or metastatic urothelial carcinoma (UC) whose disease did not progress on induction chemotherapy. 

Urothelial/Bladder Carcinoma (UC) is the most common type of urinary cancer with an occurrence rate of 90%. Immunomedics, BMS, Rexahn Pharmaceuticals are some other pharma companies developing therapies to advance Urothelial carcinoma market.